The eight new ACIP members met for the first time June 25 after Kennedy fired all 17 original members of the committee June 9 ...

A newly configured federal vaccine panel's June 25 action is expected to improve options to protect infants from potentially deadly RSV.

When Beyfortus was approved over the summer, AstraZeneca and Sanofi, the two companies that manufacture the drug, said it would be available for babies in time for RSV season this year.

Learn about cost, dosage, side effects, and more for Beyfortus, a prescription drug used to prevent respiratory syncytial virus (RSV) in certain children.

Sanofi said Beyfortus duration of protection was extended for six months in the EU. This year’s EU shipments are marked by an important change to the Beyfortus EU label, extending the duration ...

Sanofi’s SNY stock has been trading below its 200-day and 50-day moving averages since early June. On June 23, the stock’s closing price of $48.18 was below its 50-day moving average of $50.32 and the ...

Beyfortus public health advantage bolstered by first real-world comparison of infant vs maternal RSV immunization programs Late-breaking data show infant respiratory syncytial virus (RSV ...

Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season Paris, June 9, 2025. Sanofi is shipping Beyfortus (nirsevimab) starting in ...

Beyfortus public health advantage bolstered by first real-world comparison of infant vs maternal RSV immunization programs Late-breaking data show infant respiratory syncytial virus (RSV) ...

Sanofi boosts Beyfortus output for RSV season while Dupixent trial shows strong eczema relief in patients with skin of color.

Sanofi said Beyfortus duration of protection was extended for six months in the EU. This year’s EU shipments are marked by an important change to the Beyfortus EU label, extending the duration ...